BioVision is dedicated to advancing scientific research through the development of high-performance biochemical and cell-based assays. Their product portfolio includes a wide range of off-the-shelf kits designed to facilitate reproducible science, enabling researchers in both academia and the biopharma industry to generate robust data efficiently. The company emphasizes the importance of innovation in their offerings, which are tailored to meet the evolving needs of the life sciences sector, particularly in response to the increased demand for effective workflows and rapid results.

In addition to their extensive product range, BioVision is committed to building long-term partnerships within the scientific community. This collaborative approach not only enhances their innovation capabilities but also supports the global research community by providing access to their advanced assays through a comprehensive commercialization network. The recent acquisition by Abcam further strengthens BioVision's position in the market, allowing for expanded resources and facilities that will enhance their ability to support scientific breakthroughs and contribute positively to health and science advancements.

United States

BioVision is now part of Abcam.

BioVision is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. Founded in 1995, BioVision specializes in the supply and integration of high quality imaging technologies to support research. In August 2021, Abcam acquired BioVision for $340 million, and it is now part of Abcam.

BioVision

Company Details